Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076431" target="_blank" >RIV/65269705:_____/22:00076431 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/22:00128095
Result on the web
<a href="https://www.futuremedicine.com/doi/10.2217/fon-2022-0450" target="_blank" >https://www.futuremedicine.com/doi/10.2217/fon-2022-0450</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/fon-2022-0450" target="_blank" >10.2217/fon-2022-0450</a>
Alternative languages
Result language
angličtina
Original language name
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia
Original language description
Prevention of relapse is a major therapeutic challenge and an unmet need for patients with acute myeloid leukemia (AML). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis in AML cells. When combined with azacitidine, it leads to prolonged overall survival and rapid, durable remissions in treatment-naive AML patients ineligible for intensive chemotherapy. VIALE-M is a randomized, double-blind, two-arm study to evaluate the safety and efficacy of venetoclax in combination with oral azacitidine (CC-486) as maintenance therapy in patients in complete remission with incomplete blood count recovery after intensive induction and consolidation therapies. The primary end point is relapse-free survival. Secondary outcomes include overall survival, minimal residual disease conversion and improvement in quality-of-life.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Future Oncology
ISSN
1479-6694
e-ISSN
1744-8301
Volume of the periodical
18
Issue of the periodical within the volume
26
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
2879-2889
UT code for WoS article
000827070200001
EID of the result in the Scopus database
2-s2.0-85135596293